ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs that will dramatically extend and improve the lives of patients in areas of high unmet need.With four internally discovered drugs in multiple biomarker guided clinical trials and an enriched proprietary kinase library from which to select additional drug candidates, ArQule is delivering on the potential of precision medicine by providing its patients with novel therapies for multiple hard to treat indications and its shareholders with a focused, highly efficient and cost effective research and development strategy. ArQule is led by a senior management team with significant clinical and commercial expertise that provides the leadership required to optimize its opportunities for success in a rapidly changing and highly competitive field. Source
No articles found.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, de...
Entasis is a clinical-stage biopharmaceutical c...
The mission of Cassava Sciences is to detect and treat neurodegenerative diseases,...
The mission of Cassava Sciences is to detect an...
As of June 30, 2019, Sabraâs investment portfolio included 432 real estate prope...
As of June 30, 2019, Sabraâs investment portf...
BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat...
BioCryst Pharmaceuticals discovers novel, oral ...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
Mustang Bio, Inc. (âMustangâ), a Fortress Biotech Company, is a clinical-stage...
Mustang Bio, Inc. (âMustangâ), a Fortress B...
CTI BioPharma is a biopharmaceutical company focused on the acquisition, developme...
CTI BioPharma is a biopharmaceutical company fo...
Join the National Investor Network and get the latest information with your interests in mind.